Astellas and FibroGen’s Evrenzo (roxadustat) Receives MHLW’s Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients

Astellas and FibroGen’s Evrenzo (roxadustat) Receives MHLW’s Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients

Shots:

  • The approval is based on four P-III studies evaluating Evrenzo (20/50/100mg) in CKD anemic patients on dialysis in Japan, demonstrating increment in hemoglobin level and is well tolerated among the patients, marking the first approval of the collaboration
  • Astellas and FibroGen collaborated to develop Evrenzo for treating anemia in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa while FibroGen collaborated with AstraZeneca for Evrenzo in the US, China & other markets
  • Evrenzo (PO) is a HIF-PH inhibitor, approved for anemia associated with CKD in both dialysis-dependent and non-dialysis-dependent patients with anticipates approval in the US & EU

Click here to­ read full press release/ article | Ref: Astellas | Image: Great Place to Work